Inhibikase Therapeutics Shares Rise on $50M At‑the‑market Share Sale
Dow Jones
Jul 14
Shares of Inhibikase Therapeutics rose after the company said it sold 25 million of its common shares to RA Capital Management through its at-the-market sales program for gross proceeds of $50 million.
Shares were recently up 12% at $2.19 late Tuesday morning. The stock is up about 29% over the past three months.
Inhibikase said the additional capital, together with existing cash, is expected to support operations through the topline data readout in Part B of its global Phase 3 study in pulmonary arterial hypertension. That assumes the outstanding Series A and B warrants are fully exercised.
Write to Doc Louallen at Doc.Louallen@wsj.com
(END) Dow Jones Newswires
July 14, 2026 11:10 ET (15:10 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.